Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression

Ignacio Iñigo-Marco1,2,3 and Marta M. Alonso1,2,3

Navarra’s Health Research Institute (IDISNA) Pamplona, Spain. 2Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Spain. 3Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain.

Tumor-induced immunosuppression is a common obstacle for cancer treatment. Adrenergic signaling triggered by chronic stress participates in the creation of an immunosuppressive microenvironment by promoting myeloid-derived suppressor cell (MDSC) proliferation and activation. In this issue of the JCI, Mohammadpour et al. elegantly delve into the mechanisms underlying MDSC contribution to tumor development. They used in vitro and in vivo mouse models to demonstrate that chronic stress results in MDSC accumulation, survival, and immune-inhibitory activity. Of therapeutic relevance, the authors showed that propranolol, a commonly prescribed β-blocker, can reduce MDSC immunosuppression and enhance the effect of other cancer therapies.

Chronic adrenergic stress impacts cancer progression

Chronic adrenergic stress has a deleterious effect on the immune system that impacts cancer progression, metastasis, and drug resistance (1, 2). Supporting this notion, previous studies showed that activating adrenergic receptors (ARs), which are broadly expressed in innate and adaptive immune cells and predominantly β2-AR, inhibits effector immune cells and promotes immunosuppressive cell activity (2). For example, β2-AR activation leads to metabolic deprivation and decreased secretion of IFN-γ by CD8+ T cells (3), impaired dendritic cell (DC) maturation (4), and increased myeloid-derived suppressor cell (MDSC) recruitment (5). In fact, many conventional anticancer therapies, as well as new immunotherapies, fail because the immune system is unable to fight the tumor. Tumors usually take advantage of immune system control mechanisms to create an appropriate microenvironment that favors cell survival and tumor growth (6). Tumors thrive in the presence of immunosuppressive cells and signals that inhibit apoptosis, promote angiogenesis, and prevent the recruitment of cytotoxic cells.

Bridging stress and immunosuppression

In this issue of the JCI, Mohammadpour et al. (7) go a step further to bridge stress and immunosuppression, dissecting the functional link between adrenergic stress and MDSCs in tumor development. The authors used orthotopic breast cancer mouse models and β2-AR–/– knockout mice, to demonstrate that stress caused by housing mice in subthermal conditions (22°C) has a protumorigenic effect. They also showed adrenergic regulation of MDSCs as an effective strategy to restrain tumor growth and support other anticancer therapies (Figure 1) (7).

MDSCs are a heterogeneous group of immature myeloid cells. Given the appropriate signaling, these cells are able to differentiate into granulocytes, macrophages and dendritic cells. Due to their immunosuppressive effects on the tumor microenvironment (TME) and their ability to promote tumor growth and dissemination, MDSCs are attracting much attention in cancer research. Aside from their direct immunosuppressive effects, they also indirectly promote tumorigenesis by acting upon other immune cells involved in tumor immunity; MDSCs secrete anti-inflammatory cytokines such as IL-10 and TGF-β, affect NK function, attract Tregs, and suppress cytotoxic cells, among other functions.

Mohammadpour et al. thoroughly studied the role of MDSCs in a murine breast cancer model. They concluded that upon adrenergic stimulation, MDSCs activate and proliferate, leading to an overall protumoral microenvironment. Unlike MDSCs from β2-AR–/– mice, MDSCs from WT mice presented several oncogenic features and exhibited increased expression of β2-AR and tumoral markers, such as Arg-I, PDL-1, and BCL-2, among others (7).

Mohammadpour and colleagues revealed that MDSC protumoral changes depend on adrenergic-induced STAT3 phosphorylation (7). This finding seems reasonable since STAT3 is a transcription factor known to promote MDSC proliferation and survival while restraining their differentiation. Notably, STAT3 inhibition is harmless to normal cells. However, inhibiting STAT3 can trigger MDSCs to differentiate into tumor-associated macrophages (TAMs), which are myeloid cells that also play a preferentially immunosuppressive role in tumors (8). Therefore, inhibiting STAT3 would inhibit MDSC proliferation, but also increase the number of TAMs, which could have their own detrimental effects. If the overactivation of STAT3 found in tumors promotes MDSC proliferation but STAT3 inhibition induces MDSC differentiation into TAMs, what is less damaging: MDSC or TAM proliferation? Clinically targeting STAT3 to modulate MDSCs is an appealing strategy to...
of cells, including immune cells, in which β2-AR is the most highly expressed adrenergic receptor (15). Chronic adrenergic stress acts upon most of these immune cell types, compromising their function and leading to a poor patient outcome (1). Mohammadpour et al. confirm increased tumor growth under adrenergic stress. They showed that stress-promoting conditions increased MDSC proliferation and activation, as well as protumoral cytokine levels in plasma and tumor. Conversely, none of these effects are observed in β2-AR–/– mice, which present a better outcome in terms of tumor growth, protumoral cytokine levels, and lung metastasis (7).

β-blockers in oncologic patients

In their paper, Mohammadpour et al. not only confirm the immunosuppressive effect of MDSCs on tumor development, but also link this detrimental effect with stress-induced adrenergic signaling, which is common in oncologic patients. More importantly, the authors efficiently targeted and reverted the immunosuppressive phenotype using β-blocking drugs (7). β-blockers, such as propranolol, have treated other pathologies such as hypertension, essential tremor, anxiety, and migraines for decades. Propranolol has minor to no side effects and translational application would be much quicker and less expensive than new drug development. Notably, oncologic patients already taking β-blockers for other pathologies may have better outcomes (16). Although only one prospective study to date has addressed this finding, the results are encouraging. A fraction of melanoma patients taking propranolol showed a significantly lower rate of cancer recurrence than those not taking the medication (17). Nevertheless, clinical trials specifically designed to evaluate the safety and effectiveness of propranolol and other

restrict immunosuppression in the TME; but if considered as a treatment option, studies should carefully check for opposing effects (9).

Mohammadpour and authors also showed that adrenergic-induced changes occur in MDSCs in both the TME and spleen (7). These changes in the spleen are remarkable since MDSCs sometimes behave differently in peripheral lymphoid organs as they do in the TME (10). MDSCs in peripheral lymphoid organs are mostly polymorphonuclear MDSCs (PMN-MDSCs), which depend on ROS-mediated immunosuppression and need antigen-specific interaction with T cells (11). In contrast, monocytic MDSCs (M-MDSCs), which are more abundant in the TME than PMN-MDSCs, have a more potent suppressive effect and rapidly differentiate into TAMs (12). Therefore, the different behavior of MDSCs between tumor and periphery certainly requires further consideration.

Most cancer patients experience high levels of stress derived from diagnosis and treatment, and stress is known to negatively affect the immune system and response to treatment. Crosstalk between the autonomic nervous system and immune response is well established (13). In fact, tumors secrete neural growth factors to attract autonomic innervation in an angiogenesis-like manner (14). These adrenergic terminals innervate lymphoid organs and ganglia, suggesting that stress signals tightly regulate the immune response. Indeed, adrenergic receptors for norepinephrine and epinephrine are expressed on the surfaces of a broad range
β-blockers in oncologic patients are necessary to elucidate the possible therapeutic value of β-blockers in a clinical context, which in turn will probably depend on many factors, such as the tumor type, disease stage, and patient age. Regardless, this study sheds light on tumor immunosuppressive mechanisms and reveals propranolol and other β-blockers as potential therapeutic tools in cancer treatment, and supports the idea of using β-blockers in those cases in which immunosuppression is an obstacle to common cancer therapies.

Mohammadpour et al. focused here on breast cancer, but the idea of translating these findings to other types of tumors in which treatment options are scarce and immunosuppression is a barrier to effective therapies, such as gliomas, is certainly exciting. Gliomas are primary brain tumors with a meager median survival and no curative therapies. Due to the highly immunosuppressed microenvironment of gliomas (reviewed in refs. 18 and 19), it would be truly interesting to see whether combining propranolol with different immunotherapy approaches could result in a curative therapy.

In closing, the work by Mohammadpour et al. provides a tangible link between chronic stress and immunosuppression, with implications in cancer progression and treatment (7). Moreover, this work challenges us to consider the stresses that accompany our daily routine and to take life with a grain of salt.

Acknowledgments
This work was supported by the Instituto de Salud Carlos III y los Fondos Feder Europeos (PI13/125 and PI16/0066 to MMA), Foundation Caja Navarra and Foundation LA CAIXA (to MMA), Foundation “El sueño de Vicky,” Association Pablo Ugarte-Fuerza Julen (to MMA), and a DOD Team Science Award (CA160525 to MMA). This work was also supported by the European Research Council under the European Union’s Horizon 2020 research and innovation programme, grant agreement 817884; ViroPedTher (to MMA).

Address correspondence to: Marta M. Alonso, Department of Pediatrics, Clinica Universidad de Navarra, CIMA Building, Avd. Pio XII, 55 Pamplona, Spain. Phone: 34.948194700.1017; Email: mmalonso@unav.es.